This review found that women treated with fertility medications may have no greater risk of ovarian cancer than untreated infertile women. While the review took steps to minimise bias, the conclusions are limited because they are based on observational data and do not account for confounding factors such as treatment regimen, parity and specific infertility diagnosis.
Results of the review
Three cohort studies (33,393 participants) and 7 case-control studies (13,480 participants) were included in the quantitative analyses.
In quality assessments, the case-control studies scored between 5 and 7 out of a possible 9 whilst the cohort studies scored either 6 or 7.
Combined data from case-control studies, based on a fixed-effect model, suggested that women with ovarian cancer may be more likely to have been treated with fertility medications than general population controls (OR 1.52, 95% CI: 1.18, 1.97). When cases were compared to controls without ovarian cancer, the risk of exposure to fertility drugs was not elevated. Data from cohort studies suggested that infertile women who received medication did not have an increased risk of ovarian cancer compared with untreated infertile women (OR 0.67, 95% CI: 0.32, 1.41).
There was no evidence of publication bias.
The Q statistic suggested no statistically significant heterogeneity.
Authors' conclusions
Compared with untreated infertile patients, there is no evidence that fertility treatment increases the risk of ovarian cancer.
CRD commentary
This review included a defined research question and inclusion criteria. However, the authors changed their inclusion criteria for eligible study designs after a preliminary literature search. The authors reported the methods used to select and assess the studies in detail. The search was thorough and included attempts to obtain unpublished material, and the review methods appeared robust. Although no publication bias was reported, the authors acknowledged that a number of unpublished studies were not included in the review. The methods used to assess and combine the studies appeared appropriate. The authors suggested a trend towards increased incidence of cancer in untreated women with fertility problems in comparison with treated women. However, the results were not statistically significant so it was questionable whether such findings should be reported as trends. The authors acknowledged that subgroup analyses may have been beneficial, but there were insufficient data to analyse findings according to drug type, treatment regimen, infertility diagnosis, or other confounders. This may limit the usefulness of the conclusions.
The review was based on observational data which cannot prove causality and, as such, the conclusions must be treated with caution or as hypothesis generating.
